Skip to content

Advertisement

  • Poster presentation
  • Open Access

Clinical depiction, treatment and long term follow up characterization of a group of enthesitis related arthritis - juvenile idiopathic arthritis patients from a spanish pediatric tertiary hospital

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 1,
  • 1,
  • 3 and
  • 1
Pediatric Rheumatology201412 (Suppl 1) :P181

https://doi.org/10.1186/1546-0096-12-S1-P181

  • Published:

Keywords

  • Etanercept
  • Juvenile Idiopathic Arthritis
  • Uveitis
  • Ethic Committee Approval
  • Juvenile Idiopathic Arthritis Patient

Introduction

Enthesitis related arthritis (ERA) is a subtype of Juvenile Idiopathic Arthritis (JIA) that affects children >6 years of age. It presents with enthesitis, uveitis, peripheral and axial arthritis. It´s one of the less frequent subtypes of JIA. Data is scarse involving follow up and outcomes.

Objectives

Describe a case series of JIA-ERA patients of a Spanish cohort in a tertiary pediatric hospital. Report response to oral (OR) and subcutaneous (SC) methotrexate (MTX) in insufficient/non-responders to NSAID/intra-articular steroid infiltrations in these patients. Relate the persistence of symptoms on follow-up and course of treatment.

Methods

Retrospective and observational.Inclusion criteria: Edmonton classification criteria for ERA-JIA. Variables: age, sex, HLA-B27, date and delay of diagnosis, onset of symptoms, classification, start/finish of date of OR MTX, start/finish date of MTX SC, date of start of biologic treatment (as a variable of MTX inefficacy). Articular activity: number of swollen joints (NSJ) and number of painful joints (NPJ). Prospective data will be collected starting January 2014 of all ERA-JIA patients visited in our Unit. Local ethics committee approval was acquired.

Results

11 patients all of which were male (100%), mean age of 15.3 (SD 4.6), age of first symptom 11.2, (SD 2.4), age of diagnosis 11.6 years (SD 2.3), delay in diagnosis 4.7 months (SD 6.3), follow up 55.6 months (SD 42.2). 90% were HLA-B27positive. The rest of the clinical data are summed up on table 1. Number of painful joints (NPJ) varied from 0-4, number of swollen joints (NSJ) between 0 and 8. 90.9% (10 patients) required MTX. Six received OR MTX (54.5%), 4 of these patients switched to SC MTX (66.7%) due to inefficacy. A total of 8 of 11 patients received SC MTX. The average dose of MTX was 14.6 mg/week (SD 3.9). Two (20%) patients continued MTX on transition to the adult rheumatology clinic. The average time on MTX was 13.1 months (SD 7.6). One patient suspended treatment with MTX because of digestive intolerance and another because of inefficacy. One patient (9%) started Etanercept because of partial response to both OR and SCMTX.

Table 1

Joint activity

NPJ at onset

NPJ at end of follow up

NSJ at onset

NSJ at end of follow up

Average

1

0

2.82

0.13

Standard deviation

1.34

0.00

3.28

0.35

Conclusion

Patients had a mean age of 11 years at time of diagnosis, are male, HLA-B27 positive and have low level joint activity. The majority of patients that started OR MTX switched to SC MTX due to inefficacy or insufficient response, with a mean weekly dose of 15mg/weekSC MTX. The rate of side effects was low (<10%). Several patients required active treatment (DMARD/biologic) after 4 years of follow-up. Our findings should be taken with a grain of salt as this analysis is preliminary and we will be completing data from all of our JIA-ERA patients in coming months.

Disclosure of interest

None declared.

Authors’ Affiliations

(1)
Pediatric Rheumatology Unit, Pediatrics Department, Hospital Sant Joan de Deu, Barcelona, Spain
(2)
Department of Rheumatology, Hospital del Mar, Barcelona, Spain
(3)
Department of Rheumatology, Hospital de Bellvitge, Barcelona, Spain

Copyright

© Baldizon et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement